Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.9%

10 terminated/withdrawn out of 92 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

4%

4 trials in Phase 3/4

Results Transparency

45%

18 of 40 completed trials have results

Key Signals

23 recruiting18 with results8 terminated

Enrollment Performance

Analytics

N/A
36(45.0%)
Phase 2
32(40.0%)
Phase 1
7(8.8%)
Phase 3
3(3.8%)
Early Phase 1
1(1.3%)
Phase 4
1(1.3%)
80Total
N/A(36)
Phase 2(32)
Phase 1(7)
Phase 3(3)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials
NCT05846789Phase 2Recruiting

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Role: collaborator

NCT06617455Phase 2Terminated

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

Role: collaborator

NCT07023822Not ApplicableCompleted

WISH, Feasibility of a Factorial Design

Role: collaborator

NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT06179303Phase 2Recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Role: collaborator

NCT07340541Phase 2Recruiting

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Role: collaborator

NCT04841148Phase 2Recruiting

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Role: collaborator

NCT07499999Phase 2Not Yet Recruiting

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

Role: collaborator

NCT03586297Completed

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Role: collaborator

NCT07320664Not ApplicableRecruiting

Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women

Role: collaborator

NCT07475325Not Yet Recruiting

Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.

Role: collaborator

NCT07482384Not ApplicableNot Yet Recruiting

Supporting Health Including Endocrine Treatment for Long Duration

Role: collaborator

NCT06218303Phase 1Recruiting

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Role: collaborator

NCT04085510Not ApplicableActive Not Recruiting

Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania

Role: collaborator

NCT03351803Active Not Recruiting

BRCA Founder OutReach (BFOR) Study

Role: collaborator

NCT06709651Recruiting

Microbiome Immunotherapy Neoadjuvant Assessment

Role: collaborator

NCT06502691Phase 1Recruiting

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Role: collaborator

NCT06099769Phase 2Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Role: collaborator

NCT05625659Not ApplicableRecruiting

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Role: collaborator

NCT03769415Not ApplicableRecruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Role: collaborator